<DOC>
	<DOCNO>NCT02224573</DOCNO>
	<brief_summary>To investigate potential antiepileptic effect cannabidiol ( GWP42003-P ) child young adult Dravet Lennox-Gastaut syndrome .</brief_summary>
	<brief_title>An Open Label Extension Study Cannabidiol ( GWP42003-P ) Children Young Adults With Dravet Lennox-Gastaut Syndromes</brief_title>
	<detailed_description>This multi-center , open label extension study patient Dravet syndrome Lennox-Gastaut syndrome previously participate double-blind , placebo-controlled clinical study GWP42003-P ( Core Studies ) . The first subject enroll open label extension study Data Safety Monitoring Committee review safety data Part A study GWEP1332 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<criteria>Key • Subject complete scheduled visit treatment phase Core Study . Key Subject currently use recreational medicinal cannabis , synthetic cannabinoid base medication ( include Sativex® ) investigational medicinal product ( IMP ) unwilling abstain duration study . Any history suicidal behavior suicidal ideation type four five CSSRS Visit 1 . Subject part clinical trial involve IMP interstudy period . Female subject child bear potential male subject 's partner child bear potential , unless willing ensure partner use effective contraception , example , oral contraception , double barrier , intra uterine device , study three month thereafter ( however male condom use conjunction female condom ) . Subject significantly impaired hepatic function 'End Treatment ' visit Core Study Visit 1 reassess : ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5 × upper limit normal ( ULN ) . ii ) ALT AST &gt; 3 × ULN ( total bilirubin [ TBL ] &gt; 2 × ULN international normalize ratio [ INR ] &gt; 1.5 ) . iii ) ALT AST &gt; 3 × ULN presence fatigue , nausea , vomit , right upper quadrant pain tenderness , fever , rash , and/or eosinophilia ( &gt; 5 % ) . This criterion must confirm prior entering study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cannabidiol</keyword>
	<keyword>CBD</keyword>
	<keyword>GWP42003-P</keyword>
</DOC>